Adverse events of statin-fenofibric acid versus statin monotherapy: A meta-analysis of randomized controlled trials

Current Medical Research and Opinion

Volumn 29, Issue 3, 2013, Pages 181-188

  Geng, Qiang ^a   Ren, Jingyi ^a   Chen, Hong ^a   Lee, Chongyou ^a   Liang, Wenqing ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Adverse events; Fenofibric acid; Meta analysis; Statin

Indexed keywords

ATORVASTATIN; CHOLINE FENOFIBRATE; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADVERSE DRUG REACTION; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUSCLE DISEASE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KIDNEY; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84873689744     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.766592     Document Type: Article

References (18)

1. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
2. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81
3. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008;5:319-35
4. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and incombination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
5. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;5:462-8
6. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818
7. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-421
8. Trilipix [Package insert]. North Chicago, IL: Abbott Laboratories, 2009. Available at: http://www.trilipixpro.com/[Last accessed 26 May 2010]
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 7:e1000097
10. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org [Last accessed 21 March 2011]
11. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-22
12. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009;204:208-15
13. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009; 157:195-203
14. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia a randomized, double blind study. Am J Cardiovasc Drugs 2010;10:175-86
15. Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study. Cardiovasc Drugs Ther 2010;24:421-8
16. Bays HE, Roth EM, McKenney JM, et al. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care 2010; 33:2113-16
17. Moutzouri E, Kei A, Elisaf MS, et al. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010;6:525-39
18. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61